VivoSim Labs (VIVS) Return on Capital Employed (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Return on Capital Employed of 261.78% for Q1 2026, down 3282.0% year-over-year from 8.23% in Q1 2025, and down 33.66% quarter-over-quarter from 195.86% in Q4 2025.
VivoSim Labs (VIVS) Return on Capital Employed (2011 - 2026) Analysis & Trends
VivoSim Labs' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 261.78% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3282.0% year-over-year to 261.78%; the TTM figure through Mar 2026 stood at 261.78% (down 3282.0% YoY), while the FY2026 annual figure was 139.52%, up 4703.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 261.78%, down from 195.86% in the prior quarter.
- The five-year high for Return on Capital Employed was 34.98% in Q1 2022, with the low at 531.67% in Q4 2024.
- The 5-year median for Return on Capital Employed is 195.86% (2025), against an average of 184.16%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 29409 bps in 2024, then surged 33581 bps in 2025.
- VivoSim Labs' Return on Capital Employed stood at 47.24% in 2022, then tumbled by 403 bps to 237.58% in 2023, then tumbled by 124 bps to 531.67% in 2024, then soared by 63 bps to 195.86% in 2025, then plunged by 34 bps to 261.78% in 2026.
- Business Quant data shows VIVS's Return on Capital Employed at 261.78% in Q1 2026, 195.86% in Q4 2025, and 145.2% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | -304.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -304.88% |
| Mar 31, 2026 | -261.78% |
| Dec 31, 2025 | -195.86% |
| Sep 30, 2025 | -145.20% |
| Jun 30, 2025 | -108.71% |
| Mar 31, 2025 | -228.97% |
| Dec 31, 2024 | -531.67% |
| Sep 30, 2024 | -224.11% |
| Jun 30, 2024 | -242.95% |
| Mar 31, 2024 | -262.14% |
| Dec 31, 2023 | -237.58% |
| Sep 30, 2023 | -271.81% |
| Jun 30, 2023 | -161.64% |
| Mar 31, 2023 | -93.20% |
| Dec 31, 2022 | -47.24% |
| Sep 30, 2022 | -43.13% |
| Jun 30, 2022 | -39.68% |
| Mar 31, 2022 | -34.98% |
| Dec 31, 2021 | -36.33% |
| Sep 30, 2021 | -31.50% |